Avidity Biosciences honors rare diseases Day® and global efforts to support people and families affected by rare neuromuscular diseases

SAN DIEGOPresent February 28, 2025 / Prnewswire/ – Avidity Biosciences, Inc. (Nasdaq: RNA), a Biopharmaceutical Committed to Delivering A New Class of RNA Therapeutics Called Antibody Oligonucleotide Conjugates (AOCS ™), deadly announced the global Community of Patients, Caregivers, Families and Healthcare Providers to Build Broader Awarness of Rare Diseases, including Rare Neuromuscular Diseases and the urgent need for more permitted treatments for many of these diseases to support the day of rare diseases.

“The day of rare illness is an important opportunity for all of us, including people who live around the world with rare diseases, their friends, their family and their supervisors and interest representation organizations to face the many challenges that are rare in everyday life,” said Sarah Boyce, President and Chief Executive Officer in Avidity. “We are still to listen to the development of a more comprehensive consciousness for the devastating effects of rare, advanced neuromuscular diseases such as DMD, DM1 and FSHD as well as rare cardiomyopathies and the many patients and nurses who help our efforts. Your optimism, courage and insights recharge your work that we do every day. “

The day of the rare disease takes place on the last day in February one year with the aim of raising awareness of the effects of rare diseases worldwide. EURORDIS founded the day of rare diseases in 2008 and coordinates more than 70 patient organizations of the national alliance every year to honor those who live with rare diseases and their families and carers. Avidity combines with members of the global community for rare diseases, including patients, caregivers, clinicians, friends and family members to support the day with rare illnesses. To find out how you can get involved, visit the website of the Eurordis Rare Disease Day here: www.rarediseaseday.org.

When recognizing the day for rare diseases, Avidity supports a number of activities in order to sharpen a broader awareness of rare diseases such as DMD, DM1 and FSHD, such as: B.:

• Supported the Everyylife Foundation for rare diseases “Rare week of illness on the Capitol Hill“That took place 24.-26. February 2025 In Washington, DC
• Sponsoring of the Jett Foundation webinar “Guard with Duchenne” is kept today, February 28, 2025Including a panel discussion with people affected by DMD who share their experiences.
• Participate in EURORDIS “More than you can imagineCampaign, a global effort to support people with rare diseases and to put the power of resilience and the connection into the spotlight.
• Share perspectives of the Avidity team about our commitment to the community of rare diseases and how we are inspired by members of the patient and treatment communities.

“Leave us on the day of rare illness the commitment and work that are necessary to support those affected by rare diseases around the world,” said Luisa LealFounder and CEO of the Akari Foundation. “We are rare alone, but the partnership between organizations, industry, researchers and health service providers for rare diseases makes a profound difference in promoting innovations and hope for those who are most in need. At Akari we are working on emphasizing the importance of creating a world in which people who are affected by Duchenne muscle dystrophy and other rare diseases, regardless of their culture or background, have access to new and promising treatments as well as education and support. We are proud to work with industry leaders such as avidity in order to raise awareness and combine the global community for rare diseases in order to achieve a better, better future. “